Oral antirheumatic ‘Xeljanz’ settles the Big 4 hospitals in 9 months
Pfizer Pharmaceuticals Korea’s ‘Xeljanz(generic name: tofacitinib),’ an oral rheumatoid arthritis treatment, has been safely landed in the Big 4 hospitals within 9 months of the launch on March.
According to the medical industry on the 28th, Severance Hospital, on the 28th, unveiled pharmaceutic...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
